Alice Loo
Overview
Explore the profile of Alice Loo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
4517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jahnke W, Paladini J, Habazettl J, Wiget A, Loo A, Cowan Jacob S, et al.
Angew Chem Int Ed Engl
. 2022 Oct;
61(46):e202117276.
PMID: 36257909
Soellner published on the interplay between allosteric and adenosine triphosphate (ATP)-competitive inhibitors of ABL kinase, showing that the latter preferably binds to different conformational states of ABL compared to allosteric...
2.
Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, et al.
Clin Cancer Res
. 2020 Oct;
27(1):342-354.
PMID: 33046519
Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently feedback activated in...
3.
Palmer A, Plana D, Gao H, Korn J, Yang G, Green J, et al.
Cancer Res
. 2020 Aug;
80(19):4278-4287.
PMID: 32747364
Advanced ovarian cancers are a leading cause of cancer-related death in women and are currently treated with surgery and chemotherapy. This standard of care is often temporarily successful but exhibits...
4.
Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, et al.
Sci Adv
. 2020 Jul;
6(25):eabb2210.
PMID: 32704543
Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor-positive breast cancers. In contrast, triple-negative breast cancers (TNBCs) are resistant to CDK4/6 inhibition. Here, we...
5.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2020 Apr;
11(14):1289.
PMID: 32292577
[This corrects the article DOI: 10.18632/oncotarget.26215.].
6.
Ye L, Reznik E, Korn J, Lin F, Yang G, Malesky K, et al.
Oncotarget
. 2020 Feb;
11(4):443-451.
PMID: 32064048
There is a compelling need for new therapeutic strategies for glioblastoma multiforme (GBM). Preclinical target and therapeutic discovery for GBMs is primarily conducted using cell lines grown in serum-containing media,...
7.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2018 Nov;
9(81):35226-35240.
PMID: 30443290
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone...
8.
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob S, et al.
J Med Chem
. 2018 Aug;
61(18):8120-8135.
PMID: 30137981
Chronic myelogenous leukemia (CML) arises from the constitutive activity of the BCR-ABL1 oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have transformed CML into a chronic manageable disease....
9.
Wylie A, Schoepfer J, Jahnke W, Cowan-Jacob S, Loo A, Furet P, et al.
Nature
. 2017 Mar;
543(7647):733-737.
PMID: 28329763
Chronic myeloid leukaemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of...
10.
Burks H, Abrams T, Kirby C, Baird J, Fekete A, Hamann L, et al.
J Med Chem
. 2017 Mar;
60(7):2790-2818.
PMID: 28296398
Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo. We outline the...